Abvc announces the approval of the plan for gmp production facilities of vitargus by taiwan science park administration

Fremont, ca, aug. 03, 2023 (globe newswire) -- via newmediawire - abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology, and ophthalmology, announced that the science park administration in taiwan approved the plan for setting up a pilot good manufacturing practice (gmp) facility to produce vitargus®, a groundbreaking product in retinal detachment surgery, and to pursue the process development work for manufacturing optimization. the plan, proposed by abvc's taiwan affiliate and co-development partner, biofirst corporation, is to upgrade vitargus'® manufacturing processes so that ultimately, it can handle the global market supply of vitargus®. the factory is located in hsinchu biomedical science park, taiwan and biofirst corporation is targeting to complete the construction in 2024.
ABVC Ratings Summary
ABVC Quant Ranking